428 related articles for article (PubMed ID: 35303962)
1. CAR-NK cells for cancer immunotherapy: from bench to bedside.
Zhang L; Meng Y; Feng X; Han Z
Biomark Res; 2022 Mar; 10(1):12. PubMed ID: 35303962
[TBL] [Abstract][Full Text] [Related]
2. CAR-NK cells for acute myeloid leukemia immunotherapy: past, present and future.
Zhang L; Meng Y; Yao H; Zhan R; Chen S; Miao W; Ma S; Xu X; Li Y; Yu M; Han Y; Su W; Han Z; Wang T; Song B; Wang P; Cai H; Yan J
Am J Cancer Res; 2023; 13(11):5559-5576. PubMed ID: 38058830
[TBL] [Abstract][Full Text] [Related]
3. Chimeric antigen receptor natural killer cells: a promising antitumor immunotherapy.
Wang Y; Jin S; Zhuang Q; Liu N; Chen R; Adam SA; Jin J; Sun J
MedComm (2020); 2023 Dec; 4(6):e422. PubMed ID: 38045827
[TBL] [Abstract][Full Text] [Related]
4. Novel insights in CAR-NK cells beyond CAR-T cell technology; promising advantages.
Ebrahimiyan H; Tamimi A; Shokoohian B; Minaei N; Memarnejadian A; Hossein-Khannazer N; Hassan M; Vosough M
Int Immunopharmacol; 2022 May; 106():108587. PubMed ID: 35149294
[TBL] [Abstract][Full Text] [Related]
5. From CAR-T Cells to CAR-NK Cells: A Developing Immunotherapy Method for Hematological Malignancies.
Lu H; Zhao X; Li Z; Hu Y; Wang H
Front Oncol; 2021; 11():720501. PubMed ID: 34422667
[TBL] [Abstract][Full Text] [Related]
6. CAR-NK Cells: From Natural Basis to Design for Kill.
Khawar MB; Sun H
Front Immunol; 2021; 12():707542. PubMed ID: 34970253
[TBL] [Abstract][Full Text] [Related]
7. CAR-NK Cell: A New Paradigm in Tumor Immunotherapy.
Marofi F; Al-Awad AS; Sulaiman Rahman H; Markov A; Abdelbasset WK; Ivanovna Enina Y; Mahmoodi M; Hassanzadeh A; Yazdanifar M; Stanley Chartrand M; Jarahian M
Front Oncol; 2021; 11():673276. PubMed ID: 34178661
[TBL] [Abstract][Full Text] [Related]
8. Renaissance of armored immune effector cells, CAR-NK cells, brings the higher hope for successful cancer therapy.
Marofi F; Rahman HS; Thangavelu L; Dorofeev A; Bayas-Morejón F; Shirafkan N; Shomali N; Chartrand MS; Jarahian M; Vahedi G; Mohammed RN; Shahrokh S; Akbari M; Khiavi FM
Stem Cell Res Ther; 2021 Mar; 12(1):200. PubMed ID: 33752707
[TBL] [Abstract][Full Text] [Related]
9. CAR-NK cells: a promising cellular immunotherapy in lymphoma.
Khanmohammadi S; Rezaei N
Expert Opin Biol Ther; 2023 Jan; 23(1):37-47. PubMed ID: 36453808
[TBL] [Abstract][Full Text] [Related]
10. CAR-NK cells: A promising cellular immunotherapy for cancer.
Xie G; Dong H; Liang Y; Ham JD; Rizwan R; Chen J
EBioMedicine; 2020 Sep; 59():102975. PubMed ID: 32853984
[TBL] [Abstract][Full Text] [Related]
11. Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV.
Liu D; Tian S; Zhang K; Xiong W; Lubaki NM; Chen Z; Han W
Protein Cell; 2017 Dec; 8(12):861-877. PubMed ID: 28488245
[TBL] [Abstract][Full Text] [Related]
12. Chimeric antigen receptor-engineered natural killer cells: a promising cancer immunotherapy.
Chaudhry K; Dowlati E; Bollard CM
Expert Rev Clin Immunol; 2021 Jun; 17(6):643-659. PubMed ID: 33821731
[No Abstract] [Full Text] [Related]
13. Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell.
Lin C; Zhang J
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):200-215. PubMed ID: 29378229
[TBL] [Abstract][Full Text] [Related]
14. Application of natural killer immunotherapy in blood cancers and solid tumors.
Sayegh M; Ma S; Yu J
Curr Opin Oncol; 2023 Sep; 35(5):446-452. PubMed ID: 37551952
[TBL] [Abstract][Full Text] [Related]
15. Next Generation Natural Killer Cells for Cancer Immunotherapy.
Rossi F; Fredericks N; Snowden A; Allegrezza MJ; Moreno-Nieves UY
Front Immunol; 2022; 13():886429. PubMed ID: 35720306
[TBL] [Abstract][Full Text] [Related]
16. Harnessing natural killer cells to develop next-generation cellular immunotherapy.
Liu S; Nguyen K; Park D; Wong N; Wang A; Zhou Y
Chronic Dis Transl Med; 2022 Dec; 8(4):245-255. PubMed ID: 36420177
[TBL] [Abstract][Full Text] [Related]
17. Chimeric antigen receptor-based natural killer cell immunotherapy in cancer: from bench to bedside.
Zhang B; Yang M; Zhang W; Liu N; Wang D; Jing L; Xu N; Yang N; Ren T
Cell Death Dis; 2024 Jan; 15(1):50. PubMed ID: 38221520
[TBL] [Abstract][Full Text] [Related]
18. Chimeric antigen receptor-natural killer cells: a promising sword against insidious tumor cells.
Hojjatipour T; Sharifzadeh Z; Maali A; Azad M
Hum Cell; 2023 Nov; 36(6):1843-1864. PubMed ID: 37477869
[TBL] [Abstract][Full Text] [Related]
19. CAR-NK cells from engineered pluripotent stem cells: Off-the-shelf therapeutics for all patients.
Lu SJ; Feng Q
Stem Cells Transl Med; 2021 Nov; 10 Suppl 2(Suppl 2):S10-S17. PubMed ID: 34724715
[TBL] [Abstract][Full Text] [Related]
20. High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia.
Müller S; Bexte T; Gebel V; Kalensee F; Stolzenberg E; Hartmann J; Koehl U; Schambach A; Wels WS; Modlich U; Ullrich E
Front Immunol; 2019; 10():3123. PubMed ID: 32117200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
